NEK2 is a potential pan-cancer biomarker and immunotherapy target

NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy. This study investigated the expression level, prognostic value, gene mutations, MSI, TMB, immune checkpoints and related signalling pathways of NEK2 in pan-cancer using a comprehensive bioinformatics analysis. The results indicated that NEK2 overexpression has a certain diagnostic value in a variety of cancer types; NEK2 may be a potential prognostic and immune-related biomarker for cancer patients. This study elucidated the role of NEK2 in tumorigenesis from multiple perspectives, and provided some bases for further research on the specific mechanisms of NEK2 in cancer progression and treatment.

NEK2或可成为提升肿瘤治疗疗效的潜在泛癌生物标志物（pan-cancer biomarker）与免疫治疗靶点。本研究通过全面的生物信息学分析，对泛癌队列中NEK2的表达水平、预后价值、基因突变、微卫星不稳定性（microsatellite instability，MSI）、肿瘤突变负荷（tumor mutational burden，TMB）、免疫检查点（immune checkpoints）及相关信号通路（signalling pathways）进行了系统探究。研究结果显示，NEK2过表达在多种癌症类型中具备一定的诊断价值；NEK2或可成为癌症患者潜在的预后相关及免疫相关生物标志物。本研究从多维度阐明了NEK2在肿瘤发生发展中的作用，为后续深入探究NEK2在癌症进展与治疗中的具体分子机制提供了可靠依据。